Vir Biotechnology Reports Positive Phase 2 Results for Tobevibart and Elebsiran in Hepatitis Delta
Reuters
Nov 10
<a href="https://laohu8.com/S/VIR">Vir Biotechnology</a> Reports Positive Phase 2 Results for Tobevibart and Elebsiran in Hepatitis Delta
Vir Biotechnology Inc. announced results from its Phase 2 SOLSTICE trial evaluating the combination of tobevibart and elebsiran for the treatment of chronic hepatitis delta $(CHD)$. Data presented at The Liver Meeting® of the American Association for the Study of Liver Diseases (AASLD) and published in the New England Journal of Medicine showed that 66% of participants receiving a monthly dose of the combination achieved undetectable hepatitis delta virus $(HDV)$ RNA at Week 48. The combination was well-tolerated, with no grade 3 or higher treatment-related adverse events and no treatment-related discontinuations reported. The ECLIPSE registrational program for the combination therapy is underway, with topline data expected in the first quarter of 2027. The combination has received Breakthrough Therapy and Fast Track designations from the U.S. Food and Drug Administration, as well as Priority Medicines and orphan drug designations from the European Medicines Agency.
Disclaimer: This news brief was created by Public Technologies (PUBT) using generative artificial intelligence. While PUBT strives to provide accurate and timely information, this AI-generated content is for informational purposes only and should not be interpreted as financial, investment, or legal advice. Vir Biotechnology Inc. published the original content used to generate this news brief on November 09, 2025, and is solely responsible for the information contained therein.
Disclaimer: Investing carries risk. This is not financial advice. The above content should not be regarded as an offer, recommendation, or solicitation on acquiring or disposing of any financial products, any associated discussions, comments, or posts by author or other users should not be considered as such either. It is solely for general information purpose only, which does not consider your own investment objectives, financial situations or needs. TTM assumes no responsibility or warranty for the accuracy and completeness of the information, investors should do their own research and may seek professional advice before investing.